Skip to content

Neuropsychiatric symptoms

TL;DR — Neuropsychiatric symptoms are near-universal over the course of AD: in an incident community cohort of 408 people followed 5.3 years, 97% experienced at least one symptom, point prevalence of any symptom rose from 56% at baseline to 76–87% subsequently, and five-year period prevalence was highest for depression (77%), apathy (71%) and anxiety (62%) (Steinberg 2008, PMID 17607801). They are prognostic, not incidental: psychosis (HR 2.01) and agitation/aggression (HR 2.95) predicted progression to severe dementia, and psychosis, affective symptoms and agitation each predicted earlier death (Peters 2015, PMID 25585033). Antipsychotics carry a small mortality excess in short trials (OR 1.54, 95% CI 1.06–2.23; 3.5% vs 2.3% deaths) and a larger one on continued exposure — in DART-AD, 24-month survival was 46% with continued antipsychotics versus 71% with placebo — while CATIE-AD found adverse effects offset any efficacy advantage, with no significant CGIC difference and 5% versus 16–24% discontinuation for intolerability (Schneider 2005, PMID 16234500; Ballard 2009, PMID 19138567; Schneider 2006, PMID 17035647). Newer options are modest: brexpiprazole reduced CMAI by 5.32 points more than placebo (95% CI −8.77 to −1.87, Cohen d 0.35) (Lee 2023, PMID 37930669); citalopram 30 mg worked but cost 1.05 MMSE points and 18.1 ms of QTc (Porsteinsson 2014, PMID 24549548), and escitalopram — proposed as the safer enantiomer — failed (Rajji 2025, PMID 40133524). Antidepressants for depression in dementia failed outright in HTA-SADD while increasing adverse reactions (Banerjee 2011, PMID 21764118). Person-centred care with antipsychotic review improved quality of life, agitation and total NPI at small effect sizes and saved money (Ballard 2018, PMID 29408901).

Prevalence and trajectory

From the Cache County incident dementia sample (n=408), assessed with the NPI at baseline and 1.5, 3.0, 4.1 and 5.3 years (Steinberg 2008, PMID 17607801):

Symptom Point prevalence at baseline Point prevalence at later visits 5-year period prevalence
Any symptom 56% 76–87% 97% experienced ≥1
Depression 29% 41–47% 77%
Apathy 20% up to 51% at 5.3 y 71%
Anxiety 14% 24–32% 62%
Delusions 18% 34–38% —
Hallucinations 10% 19–24% —
Agitation/aggression — fluctuated 13–24% —
Irritability — 17–27% —
Aberrant motor behaviour 7% up to 29% at 5.3 y —
Disinhibition — fluctuated 2–15% 31%
Elation — never above 1% 6%

Apathy had consistently the highest symptom severity and the steepest rise; elation and disinhibition were rare. Two implications: apathy — the least treated symptom — is among the most prevalent and severe, and symptom fluctuation (agitation, disinhibition, irritability) means single-timepoint prevalence understates lifetime exposure.

They predict outcome

In 335 incident AD cases, 68 (20%) progressed to severe dementia over follow-up. Adjusted for age at onset, dementia duration, sex, education, general medical health and APOE ε4 (Peters 2015, PMID 25585033):

Symptom in mild AD HR for progression to severe dementia HR for earlier death
Psychosis 2.01 1.54
Agitation/aggression 2.95 1.94
Affective symptoms — 1.51
Any clinically significant NPS (domain score ≥4) 2.68 1.95
Mildly symptomatic NPS (domain 1–3) — 1.45

This is association, not causation — the same underlying pathology may drive both — but it establishes that NPS mark a faster-progressing phenotype and motivates the (untested) hypothesis that treating them alters trajectory.

Antipsychotics: the central risk–benefit problem

Evidence Design Result
Mortality meta-analysis (Schneider 2005, PMID 16234500) 15 trials (9 unpublished), 10–12 weeks, 16 drug–placebo contrasts; 3,353 on drug, 1,757 on placebo Death 118 (3.5%) vs 40 (2.3%); OR 1.54 (95% CI 1.06–2.23, P=0.02); risk difference 0.01 (0.004–0.02, P=0.01). No differential risk by individual drug, severity, sample or diagnosis
Effectiveness (CATIE-AD; Schneider 2006, PMID 17035647) 421 outpatients with AD and psychosis, aggression or agitation; olanzapine (mean 5.5 mg), quetiapine (56.5 mg), risperidone (1.0 mg) or placebo; up to 36 weeks No difference in time to discontinuation for any reason (8.1 / 5.3 / 7.4 / 8.0 weeks, P=0.52). Time to discontinuation for lack of efficacy favoured olanzapine (22.1 wk) and risperidone (26.7 wk) over quetiapine (9.1) and placebo (9.0), P=0.002. Discontinuation for intolerability 24% / 16% / 18% vs 5% placebo (P=0.009). CGIC improvement 32% / 26% / 29% vs 21% placebo, P=0.22
Long-term mortality (DART-AD; Ballard 2009, PMID 19138567) 165 UK care-home residents with AD on antipsychotics randomised to continue vs switch to placebo for 12 months, followed 24–54 months 12-month cumulative survival 70% (95% CI 58–80) continued vs 77% (64–85) placebo; overall mortality significantly higher with continuation (mITT log-rank P=0.03; HR 0.58, 95% CI 0.35–0.95 favouring withdrawal). 24-month survival 46% vs 71%; 36-month survival 30% vs 59%

The three findings compose into a coherent position: antipsychotics do not reliably improve global outcome in AD (CATIE-AD), they carry a small mortality excess over 10–12 weeks (Schneider 2005), and that excess widens substantially with continued exposure (DART-AD). Reserving them for severe distress or danger, at the lowest effective dose, with a planned review and withdrawal attempt, is what these data support.

A 2021 Cochrane review of 24 placebo-controlled trials (6,090 participants; 17 of 26 comparisons in AD specifically, the remainder also including vascular or mixed dementia) makes the efficacy side of that bargain quantitative (Mühlbauer 2021, PMID 34918337):

Class Agitation Psychosis Somnolence Extrapyramidal symptoms Serious adverse events Death
Typical (haloperidol, thiothixene) SMD −0.36 (−0.57 to −0.15); very-low certainty SMD −0.29 (−0.55 to −0.03); low certainty RR 2.62 (1.51–4.56); moderate RR 2.26 (1.58–3.23); high RR 1.32 (0.65–2.66); low RR 1.46 (0.54–4.00); low
Atypical (risperidone, olanzapine, aripiprazole, quetiapine) SMD −0.21 (−0.30 to −0.12); moderate SMD −0.11 (−0.18 to −0.03) — negligible; moderate RR 1.93 (1.57–2.39); high RR 1.39 (1.14–1.68); moderate RR 1.32 (1.09–1.61); moderate RR 1.36 (0.90–2.05); moderate

The authors' interpretation is that apparent effectiveness in daily practice may reflect a favourable natural course, as seen in the placebo groups. The first large risperidone trial (n=625 institutionalised patients, 73% AD, 15% vascular and 12% mixed dementia; >95% FAST 6–7, i.e. severe dementia) found 1 and 2 mg/day superior to placebo on BEHAVE-AD total, psychosis and aggressiveness, with 1 mg/day the better-tolerated dose and EPS at 1 mg not significantly above placebo (Katz 1999, PMID 10084637). CATIE-AD then showed that any such scale advantage does not survive a time-to-discontinuation primary in outpatients.

The American Psychiatric Association issued a dedicated practice guideline on antipsychotics for agitation or psychosis in dementia (Reus 2016, PMID 27133416). The operational sequence that guideline literature and the DICE framework share is: characterise the symptom, search for a reversible driver, deliver non-drug care first, and reserve antipsychotics for severe distress or danger (Kales 2015, PMID 25731881). Prescribing patterns and the regulatory response are covered on guidelines and red flags and safety concerns.

Pimavanserin, an oral 5-HT2A inverse agonist and antagonist, was tested in a phase 3 discontinuation design (HARMONY) enrolling psychosis related to Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, frontotemporal dementia or vascular dementia — not AD alone. Of 392 patients treated open-label for 12 weeks, 217 of 351 (61.8%) had a sustained response and were randomised to continue or switch to placebo. Relapse occurred in 13% versus 28% (HR 0.35, 95% CI 0.17–0.73, P=0.005); the trial was stopped early for efficacy (Tariot 2021, PMID 34289275; NCT03325556). This answers a different question from CATIE-AD — whether responders relapse if the drug is withdrawn — and does not establish first-line efficacy or long-term mortality in AD specifically. QT prolongation occurred; longer trials were called for and have not displaced the antipsychotic mortality signal above.

Agitation: what else is available

Agent Trial Result Cost
Brexpiprazole 2 or 3 mg 345 patients, 123 sites, 12 weeks, 2:1 randomisation (Lee 2023, PMID 37930669) CMAI change −22.6 vs −17.3; LS mean difference −5.32 (95% CI −8.77 to −1.87), P=0.003, Cohen d 0.35. No TEAE occurred in ≥5% and more often than placebo; discontinuation for AEs 5.3% vs 4.3% Effect size small; CMAI is a 29-item frequency scale so a 5-point difference on a baseline of ~80 is proportionally modest
Citalopram 30 mg CitAD, 186 patients, 9 weeks, all receiving a psychosocial intervention (Porsteinsson 2014, PMID 24549548) NBRS-A difference −0.93 (95% CI −1.80 to −0.06, P=0.04); moderate/marked improvement on mADCS-CGIC in 40% vs 26% (OR 2.13, 1.23–3.69, P=0.01); CMAI, total NPI and caregiver distress improved; NPI agitation subscale, ADLs and rescue lorazepam use did not Cognition worsened by 1.05 MMSE points (95% CI −1.97 to −0.13, P=0.03) and QTc lengthened by 18.1 ms (6.1–30.1, P=0.01)
Escitalopram ≤15 mg S-CitAD, 173 randomised (target 392), 12 weeks after failure of a psychosocial intervention (Rajji 2025, PMID 40133524) No significant improvement in the primary endpoint Drug-related QT prolongation observed. Sample smaller than planned. The PubMed abstract's point estimate (0.08) lies outside its printed 95% CI (−0.21 to 0.06), so that internally inconsistent interval is not reproduced as an effect estimate here
Memantine Cochrane (McShane 2019, PMID 30891742) Fewer memantine-treated participants experienced agitation as an adverse event (RR 0.81, 95% CI 0.66–0.99), but memantine is not an effective treatment for agitation (CMAI benefit 0.50 points, 95% CI −3.71 to 4.71) —
Dextromethorphan–quinidine Phase 2 sequential parallel comparison, 220 patients, 10 weeks (Cummings 2015, PMID 26393847; NCT01584440) Combined-stage NPI Agitation/Aggression reduced vs placebo (z = −3.95, P<0.001). Stage 1 LS mean −1.5 (95% CI −2.3 to −0.7); stage 2 −1.6 (−2.9 to −0.3). No cognitive worsening, sedation or clinically significant QTc prolongation Falls 8.6% vs 3.9%; diarrhoea 5.9% vs 3.1%; SAEs 7.9% vs 4.7%. Preliminary 10-week result
Nabilone 1–2 mg 14-week randomised crossover, 39 patients with moderate-to-severe AD (Herrmann 2019, PMID 31182351) CMAI treatment difference −4.0 (95% CI −6.5 to −1.5, P=0.003); NPI-NH total −4.6 (−7.5 to −1.6); caregiver distress −1.7 (−3.4 to −0.07). sMMSE favoured nabilone (+1.1) but SIB in completers (n=25) favoured placebo (−4.6). CGIC improvement 47% vs 23% was not significant (P=0.09) Sedation 45% vs 16% (P=0.02). 39 participants recruited from one long-term-care facility and geriatric psychiatry clinics; cognition signal inconsistent across scales
Stepwise pain protocol Cluster RCT, 60 nursing-home units within 18 nursing homes in western Norway, 352 residents with moderate-to-severe dementia and behavioural disturbance, 8 weeks of treatment (Husebo 2011, PMID 21765198) At 8 weeks, CMAI reduction 17% vs usual care; treatment-effect estimate −7.0 (95% CI −3.7 to −10.3); NPI-NH overall severity −9.0 (−5.5 to −12.6); pain −1.3 (−0.8 to −1.7); no difference in ADLs or cognition Paracetamol, morphine, buprenorphine patch or pregabalin by stepwise protocol. Treats a driver, not "agitation" as a primary psychiatric target

The escitalopram result is instructive and easily misreported: the hypothesis was that the R-enantiomer in racemic citalopram carried the cognitive and cardiac harm, so the S-enantiomer alone should be safer and equally effective. It was neither clearly safer (QT prolongation still occurred) nor effective. A negative trial with 173 of a planned 392 participants is underpowered, and the authors say so, but the direction of the point estimate does not favour the drug.

Depression

HTA-SADD randomised participants with probable or possible AD and depression lasting ≥4 weeks (Cornell scale ≥8) across nine English centres to sertraline (target 150 mg), mirtazapine (45 mg) or placebo, all with standard care. Reduction in Cornell score at 13 weeks did not differ between placebo (n=111) and sertraline (n=107; mean difference 1.17, 95% CI −0.23 to 2.58, P=0.10) or mirtazapine (0.01, −1.37 to 1.38, P=0.99), and the null persisted to 39 weeks. Adverse reactions were more common on drug: 26% placebo versus 43% sertraline (P=0.010) and 41% mirtazapine (P=0.031), with more serious adverse events rated severe (P=0.003). Five patients in each group died by week 39. The authors' conclusion is unusually direct: first-line antidepressant use for depression in AD "should be reconsidered" (Banerjee 2011, PMID 21764118).

Depression is nonetheless the commonest NPS by period prevalence (77%) and predicts earlier death (HR 1.51) (PMID 17607801; PMID 25585033) — so the failure of drug treatment is a therapeutic gap, not evidence that the symptom does not matter.

A US multicentre trial with a different case definition reached the same null. DIADS-2 randomised 131 participants with mild-to-moderate AD and "depression of AD" to sertraline (target 100 mg) or placebo: 12-week mADCS-CGIC OR 1.01 (95% CI 0.52–1.97), CSDD median difference at 12 weeks 1.2 (P=0.41; the PubMed record prints the interval as "1.65-4.05", which does not contain its own point estimate, so no interval is reproduced here), and 24-week response 44.8% versus 35.9% (OR 1.23, 0.64–2.35) with more gastrointestinal and respiratory adverse events and more pulmonary serious adverse events on sertraline (Rosenberg 2010, PMID 20087081; Weintraub 2010, PMID 20220589). Two independent nulls, two continents, two sertraline target doses.

Apathy

ADMET 2 randomised 200 participants with AD, mild-to-moderate cognitive impairment and frequent/severe apathy to methylphenidate 10 mg twice daily or placebo for 6 months across 10 North American clinics (Mintzer 2021, PMID 34570180):

  • NPI apathy subscale: mean difference −1.25 (95% CI −2.03 to −0.47, P=0.002), with the largest decrease in the first 100 days.
  • Hazard ratio for reaching no apathy symptoms: 2.16 (95% CI 1.19–3.91, P=0.01).
  • ADCS-CGIC improvement at 6 months: OR 1.90 (95% CI 0.95–3.84, P=0.07) — not significant; the longitudinal-model mean change difference was 1.43 (1.00–2.04, P=0.048).
  • Cognition and quality of life did not differ; none of the 17 serious adverse events was drug-related.

This is one of the few positive symptom trials in AD, with a small effect on the symptom scale and an equivocal global-impression result. Given that apathy has the highest NPI severity of any symptom and rises to 51% point prevalence by 5.3 years (PMID 17607801), the size of the evidence base is disproportionate to the size of the problem.

Sleep

Suvorexant 10 mg (increasable to 20 mg) versus placebo for 4 weeks in 285 patients with probable AD dementia and insomnia, with polysomnography: least-squares mean improvement in total sleep time at week 4 was 73 minutes with suvorexant and 45 minutes with placebo (difference 28 minutes, 95% CI 11–45, P<0.01); somnolence occurred in 4.2% versus 1.4%; 97% completed (Herring 2020, PMID 31944580). A 28-minute polysomnographic gain over four weeks is a modest, objectively measured effect; longer-term safety in this population, including falls, is not established by this trial.

The Cochrane review of drug treatment for sleep in dementia (9 RCTs) places that result in a thinner evidence field (McCleery 2020, PMID 33189083): melatonin up to 10 mg has little or no effect on total nocturnal sleep time (MD 10.68 minutes, 95% CI −16.22 to 37.59; 2 studies, n=184, low certainty); trazodone 50 mg for two weeks may increase total nocturnal sleep time by 42.46 minutes (0.9–84.0) and sleep efficiency by 8.53% (1.9–15.1) in a single 30-person trial; orexin antagonists (suvorexant, lemborexant) probably increase total nocturnal sleep time by 28.2 minutes (11.1–45.3) and reduce time awake after sleep onset by 15.7 minutes (3.3–28.1) with no increase in adverse events (RR 1.29, 0.83–1.99; 2 studies, n=323). The sleep-time and wake-after-onset estimates come from a single study of n=274 — the suvorexant trial above — so they are that result restated under GRADE, not independent corroboration of it. There are no RCTs of benzodiazepines or Z-drugs in this indication despite widespread use. A separate melatonin meta-analysis reported a 24.36-minute increase in total sleep time (P=0.02) with no cognitive effect (Xu 2015, PMID 25614508); the Cochrane pooling, restricted to dementia populations with identified sleep disturbance, is the more conservative estimate.

Non-pharmacological care is the intervention with the best benefit–harm ratio

WHELD, a cluster-randomised trial in 69 UK nursing homes (847 randomised, 553 completing 9 months), delivered person-centred care training, social-interaction training and antipsychotic review through a care-staff champion model (Ballard 2018, PMID 29408901):

Outcome Effect
Quality of life (DEMQOL-Proxy, primary) Mean difference 2.54 (95% CI 0.81–4.28), P=0.0042, Cohen d 0.24
Agitation (CMAI) Mean difference −4.27 (95% CI −7.39 to −1.15), P=0.0076, Cohen d 0.23
Neuropsychiatric symptoms (NPI-NH) Mean difference −4.55 (95% CI −7.07 to −2.02), P<0.001, Cohen d 0.30
Positive care interactions (QUIS) +19.7%, P=0.03, Cohen d 0.55
Antipsychotic use Low and stable in both arms; the intervention did not reduce it
Cost Reduced compared with treatment as usual — benefits achieved with a cost saving

Benefits were greatest in moderately severe dementia. The effect sizes are small, but they are comparable to or larger than the drug effects above, with no mortality signal and lower cost. The intervention did not reduce antipsychotic prescribing, which the authors attribute to the antipsychotic-review component relying on care-home processes rather than proactive primary-care education — a design lesson for implementation.

Replication changes the agitation estimate, not the mortality warning

Early brexpiprazole trials were inconsistent: fixed 2 mg/day improved CMAI by 3.77 points versus placebo (confidence limits 0.17–7.38), 1 mg/day was null, and a flexible 0.5–2 mg/day trial missed superiority (difference −2.34, limits −5.49 to 0.82); benefit in those titrated to 2 mg was post hoc (Grossberg 2020, PMID 31708380). A later Japanese trial found dose-related differences at ten weeks: −3.7 points (95% CI −6.8 to −0.7) at 1 mg and −7.2 (−10.0 to −4.3) at 2 mg, while treatment-emergent adverse events occurred in 76.8%, 84.6% and 73.8% for 1 mg, 2 mg and placebo (Nakamura 2024, PMID 39369280). Replication supports a real short-term agitation effect, but it does not remove the class-level mortality and cerebrovascular cautions attached to antipsychotic use in dementia.

Sleep-biomarker experiments should not be read as sleep-treatment trials. In a randomised trial of 38 cognitively unimpaired adults aged 45–65 (placebo 13, suvorexant 10 mg 13, 20 mg 12), a single 20 mg dose reduced CSF Aβ by roughly 10–20% and the p-tau181:tau181 ratio by about 10–15% over intensive 36-hour sampling; phosphorylation at tau-serine-202 and tau-threonine-217 did not fall (Lucey 2023, PMID 36897120). This establishes an acute orexin-linked biomarker perturbation, not prevention of AD or durable benefit in people with dementia.

A defensible sequence

  1. Characterise the symptom precisely (apathy is not depression; agitation is not psychosis) and look for a reversible driver — pain, infection, constipation, delirium, sensory deprivation, drug effects, environmental mismatch. See red flags and safety concerns.
  2. Deliver person-centred, social and activity-based care first; it has small but real effects on quality of life, agitation and total NPS, and it saves money (PMID 29408901).
  3. Reserve antipsychotics for severe distress or risk, use the lowest dose, plan review and withdrawal, and communicate the mortality signal explicitly (PMID 16234500; PMID 19138567).
  4. For agitation, treat pain first where it is a plausible driver (PMID 21765198); brexpiprazole has the clearest positive randomised evidence with an acceptable short-term safety profile; citalopram works but with cognitive and QT costs; escitalopram does not; dextromethorphan–quinidine and nabilone have phase-2 signals that have not displaced the above (PMID 37930669; PMID 24549548; PMID 40133524; PMID 26393847; PMID 31182351).
  5. Do not start sertraline or mirtazapine reflexively for depression in AD (PMID 21764118; PMID 20087081).
  6. Consider methylphenidate for prominent apathy, with the caveat of an equivocal global-impression result (PMID 34570180).

Open questions

  • Does treating psychosis or agitation in mild AD alter progression to severe dementia, as the prognostic associations suggest it might (Peters 2015, PMID 25585033)?
  • What is the mortality risk of brexpiprazole with continued exposure? DART-AD showed the antipsychotic hazard widens beyond 12 weeks, and brexpiprazole trials are 12 weeks long (Ballard 2009, PMID 19138567; Lee 2023, PMID 37930669).
  • Was S-CitAD's null result a power problem or a true absence of effect, and does the R-enantiomer hypothesis survive it (Rajji 2025, PMID 40133524)?
  • Why did antidepressants fail so completely in dementia-related depression when they work in late-life depression without dementia — is the phenotype different (Banerjee 2011, PMID 21764118)?
  • Is apathy treatable beyond a 1.25-point NPI subscale difference, and would a purpose-built apathy outcome show more (Mintzer 2021, PMID 34570180)?
  • Do sleep interventions change daytime behaviour, caregiver burden, or amyloid clearance, or only total sleep time (Herring 2020, PMID 31944580; see amyloid biology)?
  • Why did WHELD improve outcomes without reducing antipsychotic use, and would adding proactive primary-care prescriber education change that (Ballard 2018, PMID 29408901)?
  • Does pimavanserin reduce first-line psychosis rather than only relapse in responders, and what is its long-term mortality relative to DART-AD (Tariot 2021, PMID 34289275; Ballard 2009, PMID 19138567)?
  • How much of "agitation" in nursing homes is untreated pain, given that a stepwise analgesic protocol reduced CMAI by 7 points (Husebo 2011, PMID 21765198)?

References

  1. Steinberg M, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23:170-7. PMID 17607801.
  2. Peters ME, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172:460-5. PMID 25585033.
  3. Schneider LS, et al. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-43. PMID 16234500.
  4. Schneider LS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-38. PMID 17035647.
  5. Ballard C, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8:151-7. PMID 19138567.
  6. Lee D, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80:1307-1316. PMID 37930669.
  7. Porsteinsson AP, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682-91. PMID 24549548.
  8. Rajji TK, et al. Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial. Nat Med. 2025;31:1586-1591. PMID 40133524.
  9. Banerjee S, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378:403-11. PMID 21764118.
  10. Mintzer J, et al. Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial. JAMA Neurol. 2021;78:1324-1332. PMID 34570180.
  11. Herring WJ, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020;16:541-551. PMID 31944580.
  12. Ballard C, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial. PLoS Med. 2018;15:e1002500. PMID 29408901.
  13. McShane R, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3:CD003154. PMID 30891742.
  14. Mühlbauer V, et al. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021;12:CD013304. PMID 34918337.
  15. Katz IR, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60:107-15. PMID 10084637.
  16. Reus VI, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry. 2016;173:543-6. PMID 27133416.
  17. Kales HC, et al. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369. PMID 25731881.
  18. Tariot PN, et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med. 2021;385:309-319. PMID 34289275.
  19. Cummings JL, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314:1242-54. PMID 26393847.
  20. Herrmann N, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease. Am J Geriatr Psychiatry. 2019;27:1161-1173. PMID 31182351.
  21. Husebo BS, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065. PMID 21765198.
  22. Rosenberg PB, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:136-45. PMID 20087081.
  23. Weintraub D, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18:332-40. PMID 20220589.
  24. McCleery J, et al. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2020;11:CD009178. PMID 33189083.
  25. Xu J, et al. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015;30:439-47. PMID 25614508.
  26. Grossberg GT, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week randomized trials. Am J Geriatr Psychiatry. 2020;28:383-400. PMID 31708380.
  27. Nakamura Y, et al. Brexpiprazole treatment for agitation in Alzheimer's dementia: a randomized study. Alzheimers Dement. 2024;20:8002-8011. PMID 39369280.
  28. Lucey BP, et al. Suvorexant acutely decreases tau phosphorylation and Aβ in the human CNS. Ann Neurol. 2023;94:27-40. PMID 36897120.